Get all your news in one place.
100's of premium titles.
One app.
Start reading
AAP
AAP

Waters Launches Industry-First Reversed-Phase Bioseparation Columns to Deliver Up to 3x Faster GLP-1 Characterization and 2x Faster LNP Component Analysis

  • Faster run times for GLP-1, insulin, and LNP drug substance testing accelerates biopharmaceutical development timelines and reduces production bottlenecks.
  • Delivers up to 2x increase in resolving power and sensitivity to identify and track low-level impurities for improved regulatory readiness.
  • Industry-first chemical and physical particle optimization delivers reproducible methods for increasingly complex biologics.

MILFORD, Mass., June 8, 2026 /PRNewswire/ -- 55th International Symposium on High Performance Liquid Phase Separations and Related Techniques—Waters Corporation (NYSE: WAT) today announced the launch of the BioResolve™ Peptide and GTxResolve™ Lipid Phenyl-Hexyl+ and C18+ Columns, a first-of-its-kind reversed-phase (RP) column platform designed to tackle a persistent biopharmaceutical challenge: reliably separating structurally and chemically similar impurities in GLP-1 peptides, insulin, and lipid nanoparticles (LNPs) to support the development of safe, effective drug products.

BioResolve Peptide and GTxResolve Lipid Columns are the first columns Waters has introduced to market specifically QC batch-tested for GLP-1 analysis and lipid nanoparticles, solving a longstanding customer pain point.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.